Myasthenia Gravis Epidemiology Forecast

Myasthenia Gravis Insights and Trends

• Myasthenia gravis is a chronic autoimmune neuromuscular disorder in which antibodies disrupt communication at the neuromuscular junction, primarily by targeting acetylcholine receptors (AChR) or muscle-specific tyrosine kinase (MuSK).
• According to DelveInsight’s analysis, myasthenia gravis reported nearly 300,000 diagnosed prevalent cases in the 7MM (the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan) in 2025.
• Myasthenia Gravis reported approximately 140,000 diagnosed prevalent cases in the US. The rising prevalence of myasthenia gravis is likely driven by advancements in diagnostic techniques, an expanding elderly population, possible environmental influences, hereditary risk factors, and evolving lifestyle patterns.
• In the US, severity-specific diagnosed prevalent cases of myasthenia gravis, classified according to the MGFA system, indicate that mild generalized disease accounts for the largest share. In 2025, this category represented approximately 43% of all diagnosed myasthenia gravis cases.
• The diagnosis of myasthenia gravis is mostly clinical, and laboratory investigations and procedures usually aid the clinician in confirming the clinical findings.
• Myasthenia gravis typically presents with fatigable, painless weakness, most often starting with asymmetric ptosis or diplopia. Oropharyngeal or limb involvement is less common but more frequent in late-onset or MuSK+ cases. Diagnosis hinges on clinical evaluation, supported by antibody testing and electrophysiology.

DelveInsight's ‘Myasthenia Gravis–Epidemiology Forecast – 2036’ report delivers an in-depth understanding of myasthenia gravis, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.

Geography Covered

• North America: The United States
• Europe: Germany, France, Italy, Spain and the United Kingdom
• Asia-Pacific: Japan

Myasthenia Gravis Understanding

Myasthenia Gravis Overview and Diagnosis

Myasthenia gravis is an autoimmune disease in which the immune system attacks the body’s tissues. In myasthenia gravis, the attack interrupts the connection between nerve and muscle—the neuromuscular junction. It is characterized by autoantibodies against the Acetylcholine Receptor Antibody (AChR-Ab) or against a receptor-associated protein called Muscle-specific tyrosine Kinase Antibody (MuSK-Ab).

The clinical diagnosis of myasthenia gravis is confirmed by Electromyography (EMG) studies, pharmacologic testing, and serum Ab assay. Positive results on EMG confirm a postsynaptic defect of the neuromuscular transmission, the clinical response to Cholinesterase Inhibitors (ChE-Is) supports myasthenia gravis diagnosis, and detection of specific Abs confirms myasthenia gravis and identifies ab-related subgroups. EMG confirmation is crucial in patients with neither AChR nor MuSK Abs on the standard assay.

Further details are provided in the report.

Myasthenia Gravis Epidemiology

Key Findings from Myasthenia Gravis Epidemiological Analysis and Forecast

• In the US, the anti-AchR Ab (+ve) category recorded the highest number of gMG cases at more than 76,000 cases in 2025. The anti-MuSK Ab (+ve) group recored nearly 5% cases and double seronegative group (including anti-LRP4-ab, anti-Argin-ab, and others), totaling to about 10% cases.
• According to DelveInsight’s estimates, in the US, females accounted for more than 80,000 cases and males for nearly 55,000 cases of myasthenia gravis in 2025.
• In 2025, the total number of diagnosed prevalent cases of myasthenia gravis across EU4 and the UK were recorded at nearly 130,000 cases. Germany accounted for the largest share, contributing more than 35,000 cases.
• In 2025, myasthenia gravis diagnoses across Spain showed a gender disparity, with 54% of cases occurring in females and 46% in males, highlighting a greater susceptibility among women.
• In 2025, Japan recorded the highest number of diagnosed prevalent myasthenia gravis cases under the MGFA classification in Class II, with more than 16,000 cases, followed by Class I with more than 13,000 cases.

Industry Experts and Physician Views for Myasthenia Gravis

To keep up with myasthenia gravis dynamic epidemiology trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts were contacted for insights on the myasthenia gravis epidemiology, including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.

DelveInsight’s analysts connected with 8+ KOLs to gather insights at country level. Centers such as the University of Santo Tomas, Berlin Institute of Health at Charité , Paris-Est Créteil University, UCL Queen Square Institute of Neurology etc. were contacted.

Their opinion helps understand, validate, highlight and provide epidemiological context in myasthenia gravis.

Scope of the Report

• The report covers a segment of key events, an executive summary, a descriptive overview of myasthenia gravis, explaining their causes, signs and symptoms and pathogenesis.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along diagnostic guidelines.
• The report provides an edge for understanding trends, expert insights/KOL views, and patient journeys in the 7MM.
• A detailed review of current challenges in establishing the diagnosis.

Report Insights

• Myasthenia Gravis Patient Population Forecast
• Country-wise Epidemiology Distribution
• Total Diagnosed Prevalent Cases of Myasthenia Gravis
• Severity-specific Diagnosed Prevalent Cases of Myasthenia Gravis by MGFA Classification
• Total Diagnosed Prevalent Cases of gMG
• Gender-specific Diagnosed Prevalent Cases of Myasthenia Gravis
• Age-specific Diagnosed Prevalent Cases of Myasthenia Gravis
• Diagnosed Prevalent Cases of gMG by Antibody Serology

Report Key Strengths

• Epidemiology-based (Epi-based) Bottom-up Forecasting
• 11-year forecast
• Patient Burden Trends (by geography)
• The 7MM Coverage

FAQs

Epidemiology Insights

• What is the forecast period covered in the report?
• How is epidemiological data collected and analyzed for forecasting purposes?
• Out of all EU4 countries and the UK, which country had the highest population of myasthenia gravis cases?
• What are the disease risks and burdens of myasthenia gravis?
• At what compound annual growth rate the population is expected to grow across the 7MM during the forecast period?
• What would be the forecasted patient population of myasthenia gravis at the 7MM level?

Reasons to Buy

• The report will help in developing business strategies by understanding the latest epidemiology trends.
• Insights on patient burden/ prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand KOLs’ perspectives on the dynamic epidemiology trends.
• This Artificial Intelligence (AI)   enabled report summarize and simplify complex datasets with in the report into clear, actionable insights for stakeholders, investors, and healthcare providers, enabling faster, data driven decisions.